专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明申请

WO2014152832A1 METHODS FOR IN VITRO MEMORY B CELL DIFFERENTIATION AND TRANSDUCTION WITH VSV-G PSEUDOTYPED VIRAL VECTORS 审中-公开
标题翻译：用VSV-G PSEUDOTYPED VIRAL VECTORS进行体外记忆B细胞分化和转导的方法
公开(公告)号：WO2014152832A1
公开(公告)日：2014-09-25
申请号：PCT/US2014/027910
申请日：2014-03-14
申请人： IMMUSOFT CORPORATION
发明人： XU, Mei , SCHOLZ, Matthew Rein , HERBIG, Eric J.
IPC分类号： C12P21/04 , C12N5/071 , C12N5/00
CPC分类号： C12N5/0635 , C12N2501/2302 , C12N2501/2306 , C12N2501/231 , C12N2501/2315 , C12N2501/24 , C12N2501/52 , C12N2510/02
摘要： The present disclosure relates to the in vitro differentiation of memory B cells to plasmablasts or plasma cells and genetic modification of these cells to express a protein of interest, such as a specific antibody or other protein therapeutic.
摘要翻译：本公开涉及记忆B细胞到浆细胞或浆细胞的体外分化以及这些细胞的遗传修饰以表达目的蛋白，例如特异性抗体或其它蛋白质治疗剂。

72. 发明申请

WO2010059876A3 IN VITRO HUMAN B LYMPHOPOIESIS CULTURE SYSTEM 审中-公开
标题翻译：体外人B淋巴瘤文化系统
公开(公告)号：WO2010059876A3
公开(公告)日：2010-10-14
申请号：PCT/US2009065217
申请日：2009-11-19
申请人： CALIFORNIA INST OF TECHN , LUO XIN , YANG LILI , BALTIMORE DAVID
发明人： LUO XIN , YANG LILI , BALTIMORE DAVID
IPC分类号： C12N5/0781 , C12N5/0789
CPC分类号： C12N5/0635 , C07K16/00 , C07K16/1036 , C07K16/1045 , C12N2501/056 , C12N2501/125 , C12N2501/145 , C12N2501/22 , C12N2501/23 , C12N2501/26 , C12N2501/52 , C12N2502/1394 , C12N2510/02
摘要： The present disclosure relates to systems, methods and compositions for the generation of antibody-producing B cells in vitro. Some embodiments are related to an in vitro system for generating antibody-producing B cells from hematopoietic stem/progenitor cells (HSPCs).
摘要翻译：本公开涉及体外产生抗体产生B细胞的系统，方法和组合物。一些实施方案涉及用于从造血干/祖细胞（HSPC）产生抗体产生B细胞的体外系统。

73. 发明申请

WO2009131712A3 REGULATORY B CELLS AND THEIR USES 审中-公开
标题翻译：调节B细胞及其用途
公开(公告)号：WO2009131712A3
公开(公告)日：2010-09-02
申请号：PCT/US2009002560
申请日：2009-04-27
申请人： UNIV DUKE , TEDDER THOMAS F , YANABA KOICHI , BOUAZIZ JEAN-DAVID
发明人： TEDDER THOMAS F , YANABA KOICHI , BOUAZIZ JEAN-DAVID
IPC分类号： A61K35/14 , A61P35/00 , A61P37/04
CPC分类号： A61K35/17 , A61K2035/122 , A61K2035/124 , A61K2039/505 , C07K16/2887 , C07K2317/732 , C07K2317/734 , C12N5/0087 , C12N5/0635 , C12N2501/52
摘要： The present invention relates to a phenotypically distinct CD1dhighCD5+ B cell subset that regulates T cell mediated inflammatory responses through the secretion of interleukin-10 (IL-IO). The invention also relates to the use of these IL-IO producing regulatory B cells in the manipulation of immune and inflammatory responses, and in the treatment of disease. Therapeutic approaches involving adoptive transfer of these regulatory B cells, or expansion of their endogenous levels for controlling autoimmune or inflammatory diseases and conditions are described. Ablation of this subset of regulatory B cells, or inhibition of their IL-IO production can be used to upregulate immunodeficient conditions, and/or to treat tumors/cancer. Diagnostic applications also are encompassed.
摘要翻译：本发明涉及通过分泌白细胞介素-10（IL-10）调节T细胞介导的炎性反应的表型不同的CD1dhighCD5 + B细胞亚群。本发明还涉及这些产生IL-10的调节性B细胞在免疫和炎症应答的操作以及疾病的治疗中的用途。描述了涉及过去转移这些调节性B细胞的治疗方法，或其控制自身免疫性或炎性疾病和病症的内源性水平的扩大。调节性B细胞亚群的消融或其IL-10产生的抑制可用于上调免疫缺陷状况和/或治疗肿瘤/癌症。还包括诊断应用程序。

74. 发明申请

WO2009120891A2 DIFFERENTIATION OF PRIMATE PLURIPOTENT STEM CELLS TO HEMATOPOIETIC LINEAGE CELLS 审中-公开
标题翻译：将原始细胞干细胞分化为HEMATOPOIETIC线细胞
公开(公告)号：WO2009120891A2
公开(公告)日：2009-10-01
申请号：PCT/US2009/038442
申请日：2009-03-26
申请人： GERON CORPORATION , TSENG, Suyi , MAJUMDAR, Anish, Sen , NISHIMOTO, Kevin , REDDY, Anita , LEBKOWSKI, Jane
发明人： TSENG, Suyi , MAJUMDAR, Anish, Sen , NISHIMOTO, Kevin , REDDY, Anita , LEBKOWSKI, Jane
IPC分类号： C12N5/08 , C12N5/00
CPC分类号： C12N5/0639 , A61K2039/5154 , C12N2501/02 , C12N2501/125 , C12N2501/155 , C12N2501/165 , C12N2501/22 , C12N2501/23 , C12N2501/24 , C12N2501/52 , C12N2506/02
摘要： The invention provides methods of differentiating primate pluripotent stem cells into cells of hematopoietic lineage. The invention further provides hematopoietic lineage cells differentiated from primate pluripotent stem cells, as well as methods of using the same and kits comprising the same.
摘要翻译：本发明提供了将灵长动物多能干细胞分化成造血谱系细胞的方法。本发明还提供了与灵长类动物多能干细胞分化的造血谱系细胞，以及使用它们的方法和包含该成分的试剂盒。

75. 发明申请

WO2009034172A1 ENHANCING THE T-CELLS STIMULATORY CAPACITY OF HUMAN ANTIGEN PRESENTING CELLS AND THEIR USE IN VACCINATION 审中-公开
标题翻译：增强人类抗原呈递细胞的T细胞刺激能力及其在疫苗中的使用
公开(公告)号：WO2009034172A1
公开(公告)日：2009-03-19
申请号：PCT/EP2008/062174
申请日：2008-09-12
申请人： VRIJE UNIVERSITEIT BRUSSEL , THIELEMANS, Kris, Maria, Magdalena , BONEHILL, Aude
发明人： THIELEMANS, Kris, Maria, Magdalena , BONEHILL, Aude
IPC分类号： C12N5/06 , C12N5/08
CPC分类号： C12N5/0639 , C12N2501/22 , C12N2501/23 , C12N2501/52 , C12N2501/599 , Y02A50/386 , Y02A50/403 , Y02A50/407 , Y02A50/484
摘要： With the current invention, we provide new methods of enhancing the T-cell stimulatory capacity of human dendritic cells (DCs) and their use in cancer vaccination. The method comprises the introduction of different molecular adjuvants to human DCs through transfection with at least two mRNA or DNA molecules encoding markers selected from the group of: CD40L, CD70, constitutively active TLR4 (caTLR4), IL-12p70, EL-selectin, CCR7 and/or 4-1 BBL; or in combination with inhibition of SOCS, A20, PD-L1 and/or STAT3 expression, for example through siRNA transfection. We could show a clear increase in the immunostimulatory capacity of DCs obtained in this way, enabling them to elicit an unexpectedly high T-cell immune response in vitro. Introduction of at least two of the above molecules, in combination with a tumor-specific antigen enables the DCs to elicit a significant host-mediated T-cell immune response in vivo against the tumor antigen and thus makes them very attractive in the manufacturing of anti-cancer vaccines.
摘要翻译：利用本发明，我们提供增强人树突状细胞（DC）的T细胞刺激能力及其在癌症疫苗接种中的应用的新方法。该方法包括通过用编码选自以下组的标记的标记的至少两个mRNA或DNA分子进行转染而引入不同的分子佐剂：DC40，CD70，组成型活性TLR4（caTLR4），IL-12p70，EL-选择素，CCR7 和/或4-1BBL; 或与SOCS，A20，PD-L1和/或STAT3表达的抑制的组合，例如通过siRNA转染。我们可以显示出以这种方式获得的DC的免疫刺激能力的明显增加，使得它们能够在体外引起意想不到的高T细胞免疫应答。引入至少两种上述分子与肿瘤特异性抗原结合使得DC能够在体内引起显着的宿主介导的T细胞免疫反应，抵抗肿瘤抗原，因此使得它们在制备抗体中非常有吸引力 - 癌症疫苗。

76. 发明申请

WO2008140296A1 MEANS AND METHODS FOR ENHANCING DIFFERENTIATION OF HAEMATOPOIETIC PROGENITOR CELLS 审中-公开
标题翻译：增强造血祖细胞分化的手段和方法
公开(公告)号：WO2008140296A1
公开(公告)日：2008-11-20
申请号：PCT/NL2007/050228
申请日：2007-05-16
申请人： PANGENETICS B.V. , MEERS, Stef
发明人： MEERS, Stef
IPC分类号： C12N5/06 , A61K39/00
CPC分类号： C07K16/2878 , A61K39/39541 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/75 , C07K2317/76 , C12N5/0634 , C12N2501/52
摘要： The invention provides means and method for stimulating the production of differentiated haematopoietic cells in a culture comprising haematopoietic progenitor cells, lymphocytes (preferably T-cells) and monocytes/macrophages and/or dendritic cells. The methods involve among others culturing said cells or precursors thereof in the presence of a binding molecule specific for a co-stimulatory molecule expressed on said monocytes/macrophages and/or dendritic cells or said lymphocytes (preferably T-cells).
摘要翻译：本发明提供了用于刺激包含造血祖细胞，淋巴细胞（优选T细胞）和单核细胞/巨噬细胞和/或树突细胞的培养物中分化的造血细胞产生的手段和方法。所述方法涉及在存在对所述单核细胞/巨噬细胞和/或树突细胞或所述淋巴细胞（优选T细胞）上表达的共刺激分子具有特异性的结合分子的情况下培养所述细胞或其前体。

77. 发明申请

WO2007117682A3 MATURE DENDRITIC CELL COMPOSITIONS AND METHODS FOR CULTURING SAME 审中-公开
标题翻译：成熟的细胞组合物及其培养方法
公开(公告)号：WO2007117682A3
公开(公告)日：2008-10-16
申请号：PCT/US2007008734
申请日：2007-04-06
申请人： ARGOS THERAPEUTICS INC , KIRIN PHARMA KK , HEALEY DONALD , TCHEREPANOVA IRINA , HINOHARA ATSUSHI , ADAMS MELISSA , DEBENEDETTE MARK
发明人： HEALEY DONALD , TCHEREPANOVA IRINA , HINOHARA ATSUSHI , ADAMS MELISSA , DEBENEDETTE MARK
IPC分类号： A01N43/04 , A01N63/00 , A01N65/00 , A61K38/00 , C12N5/00 , C12N5/0784 , C12N15/00
CPC分类号： C12N5/0639 , A61K2039/5154 , A61K2039/5156 , A61K2039/5158 , C12N2501/24 , C12N2501/52 , C12N2510/00
摘要： This invention provides novel CD40L polypeptides and nucleic acids, as well as antigen presenting cells and vaccines comprising such CD40L polypeptides and/or nucleic acids, and related methods for preparing the antigen presenting cells and vaccines. The antigen presenting cells and vaccines are useful for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g., mRNA or DNA), an agonistic antibody to CD40 receptor or by CD40 ligand polypeptide. The enriched populations can be further modified by the administration of an immunogen to the DC. The DC will take up and process the immunogen on its cell surface.
摘要翻译：本发明提供了新的CD40L多肽和核酸，以及包含这种CD40L多肽和/或核酸的抗原呈递细胞和疫苗，以及用于制备抗原呈递细胞和疫苗的相关方法。抗原呈递细胞和疫苗可用于增强免疫应答。本发明提供了一种制备成熟树突状细胞（DCs）的方法，其包括以下顺序步骤：（a）用包含干扰素γ受体（IFN-αR）激动剂和/或细胞的第一信号将分离的未成熟树突状细胞（iDC）肿瘤坏死因子α受体（TNF-αR）激动剂产生信号传导的树突状细胞; 和（b）用包含有效量的CD40激动剂的第二瞬时信号发信号通知所述信号传导的树突状细胞以产生CCR7 +成熟树突状细胞。本发明还提供了通过本发明的方法制备的富含树枝状细胞的群体。这种树突细胞具有增强的免疫刺激性能和增加的IL-12分泌和/或降低的IL-10分泌。可以由编码CD40L的外源多核苷酸（例如mRNA或DNA），CD40受体的激动性抗体或CD40配体多肽翻译的一种或多种多肽来启动CD40信号传导。可以通过向DC施用免疫原来进一步修饰富集的群体。 DC将占据并处理细胞表面的免疫原。

78. 发明申请

WO2005037989A3 BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS 审中-公开
标题翻译：结合域 - 免疫球蛋白融合蛋白
公开(公告)号：WO2005037989A3
公开(公告)日：2007-05-03
申请号：PCT/US0324918
申请日：2003-07-26
申请人： TRUBION PHARMACEUTICALS INC , LEDBETTER JEFFREY A , HAYDEN-LEDBETTER MARTHA S , THOMPSON PETER A
发明人： LEDBETTER JEFFREY A , HAYDEN-LEDBETTER MARTHA S , THOMPSON PETER A
IPC分类号： C07K16/00 , C12N15/09 , A61K35/12 , A61K38/00 , A61K39/00 , A61K39/395 , A61P35/00 , C07H21/04 , C07K16/28 , C07K16/46 , C12N5/0783 , C12N5/10 , C12N15/00 , C12N15/63
CPC分类号： C07K16/3061 , A61K38/00 , A61K39/0011 , A61K2039/505 , A61K2039/5152 , A61K2039/5156 , A61K2039/5158 , C07K16/2809 , C07K16/2818 , C07K16/2878 , C07K16/2896 , C07K16/462 , C07K2317/22 , C07K2317/24 , C07K2317/53 , C07K2317/622 , C07K2317/64 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/30 , C12N5/0636 , C12N2501/23 , C12N2501/51 , C12N2501/515 , C12N2501/52 , C12N2502/11 , C12N2510/00
摘要： The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.
摘要翻译：本发明涉及新型结合域 - 免疫球蛋白融合蛋白，其特征在于一种同源结构如结合抗原，反向受体等的结合域，野生型IgG1，IGA或IgE铰链区多肽或突变型IgG1铰链区多肽具有零个，一个或两个半胱氨酸残基，以及免疫球蛋白CH2和CH3结构域，并且其能够具有ADCC和/或CDC，同时主要作为其形成二硫键连接多聚体的能力受损的多肽。可以以高表达水平重组产生融合蛋白。还提供了相关的组合物和方法，包括融合蛋白的细胞表面形式和融合蛋白的免疫治疗应用以及编码这种融合蛋白的多核苷酸。

79. 发明申请

WO2007025554A1 METHOD FOR THE GENERATION OF ANTIGEN-SPECIFIC T-CELLS AND USES THEREOF 审中-公开
标题翻译：用于产生抗原特异性T细胞的方法及其用途
公开(公告)号：WO2007025554A1
公开(公告)日：2007-03-08
申请号：PCT/EP2005/009289
申请日：2005-08-29
申请人： MEDIZINISCHE HOCHSCHULE HANNOVER , GRETEN, Tim , KORANGY, Firouzeh
发明人： GRETEN, Tim , KORANGY, Firouzeh
IPC分类号： C12N5/08 , C12N5/06 , C07K14/705 , A61K45/00 , C12N15/09 , A61K48/00
CPC分类号： C12N5/0636 , A61K2039/5158 , C12N5/0634 , C12N2501/23 , C12N2501/50 , C12N2501/52 , C12N2502/99
摘要： The present invention relates to the generation and expansion of antigen-specific T-cells. Furthermore, the present invention relates to the use of antigen-specific T-cells obtained with the method according to the present invention in adoptive cell transfer therapy and in the treatment of various disorders and diseases including infections and cancer. Moreover, the present invention provides for kits and its use for generating and expanding antigen-specific T-cells. The present invention allows for the generation of antigen-specific T-cells suitable for adoptive cell transfer. The methods for the generation and expansion of antigen-specific T-cells include both in vitro and in vivo approaches.
摘要翻译：本发明涉及抗原特异性T细胞的产生和扩增。此外，本发明涉及使用根据本发明的方法获得的抗原特异性T细胞在过继细胞转移治疗中的用途以及治疗各种疾病和疾病，包括感染和癌症。此外，本发明提供试剂盒及其用于产生和扩增抗原特异性T细胞的用途。本发明允许产生适合于过继性细胞转移的抗原特异性T细胞。用于产生和扩增抗原特异性T细胞的方法包括体外和体内方法。

80. 发明申请

WO2005023865A3 ANTIBODY-PRODUCING CELL LINES EXPRESSING ACTIVATION-INDUCED-CYTIDINE-DEAMINASE AND A DOMINANT NEGATIVE ALLELE OF A MISMATCH REPAIR GENE 审中-公开
标题翻译：抗生素产生细胞系，表达激活诱导的酪氨酸脱氧尿苷酶和错配维持基因的主要负性细胞
公开(公告)号：WO2005023865A3
公开(公告)日：2005-08-18
申请号：PCT/US2004028905
申请日：2004-09-03
申请人： MORPHOTEK INC , GRASSO LUIGI , NICOLAIDES NICHOLAS C , SASS PHILIP M
发明人： GRASSO LUIGI , NICOLAIDES NICHOLAS C , SASS PHILIP M
IPC分类号： C07H21/04 , C07K16/00 , C07K16/42 , C12N5/12 , C12N5/16 , C12N15/10
CPC分类号： C12N15/1024 , C07H21/04 , C07K16/00 , C07K16/4291 , C12N5/12 , C12N2501/052 , C12N2501/15 , C12N2501/23 , C12N2501/52 , C12N2510/02
摘要： Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. Cells may be selected for expression of activation-induced cytidine deaminase (AID), stimulated to produce AID, or manipulated to express AID for further enhancement of hypermutability. These methods are useful for generating genetic diversity within immunoglobulin genes directed against an antigen of interest to produce altered antibodies with enhanced biochemical activity. Moreover, these methods are useful for generating antibody-producing cells with increased level of antibody production.
摘要翻译：人类错配修复基因的主要阴性等位基因可用于产生超可变细胞和生物体。可以选择细胞用于表达活化诱导的胞苷脱氨酶（AID），刺激产生AID，或操纵以表达AID以进一步增强超敏性。这些方法可用于在针对感兴趣的抗原的免疫球蛋白基因内产生遗传多样性，以产生具有增强的生化活性的改变的抗体。此外，这些方法可用于产生具有增加的抗体产生水平的产生抗体的细胞。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式